000147393 001__ 147393
000147393 005__ 20240229112649.0
000147393 0247_ $$2doi$$a10.3174/ajnr.A6286
000147393 0247_ $$2pmid$$apmid:31649159
000147393 0247_ $$2ISSN$$a0195-6108
000147393 0247_ $$2ISSN$$a1936-959X
000147393 0247_ $$2altmetric$$aaltmetric:69437930
000147393 037__ $$aDKFZ-2019-02510
000147393 041__ $$aeng
000147393 082__ $$a610
000147393 1001_ $$aStock, A.$$b0
000147393 245__ $$aImaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort.
000147393 260__ $$aOak Brook, Ill.$$bSoc.$$c2019
000147393 3367_ $$2DRIVER$$aarticle
000147393 3367_ $$2DataCite$$aOutput Types/Journal article
000147393 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577094642_18928
000147393 3367_ $$2BibTeX$$aARTICLE
000147393 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000147393 3367_ $$00$$2EndNote$$aJournal Article
000147393 500__ $$a40(11):1811-1817
000147393 520__ $$aIn addition to the 4 histopathologically defined entities of medulloblastoma, 4 distinct genetically defined subgroups have been included in the World Health Organization classification of 2016. The smallest subgroup is the medulloblastoma with activated wingless pathway. The goal of this study was to identify a typical MR imaging morphology in a larger number of pediatric patients with wingless pathway medulloblastoma.From January 2001 to October 2017, of 75 patients with histologically confirmed and molecularly subgrouped wingless pathway medulloblastomas recruited to the German Pediatric Brain Tumor (HIT) trials, 38 patients (median age, 12.8 ± 4.6 years at diagnosis; 24 [63.2%] female) had preoperative imaging that passed the entry criteria for this study. Images were rated by the local standardized imaging criteria of the National Reference Center of Neuroradiology. Additionally, a modified laterality score was used to determine tumor localization and extension.Twenty-eight of 38 (73.7%) were primary midline tumors but with a lateral tendency in 39.3%. One extensively eccentric midline tumor was rated by the laterality score as in an off-midline position. Five tumors were found in the cerebellopontine angle; 3, in the deep white matter; and 2, in a cerebellar hemisphere. Leptomeningeal dissemination was rare (11.5%). In 60.5%, intratumoral blood-degradation products were found, and 26.3% showed cysts with blood contents.According to our observations, wingless pathway medulloblastomas are not preferentially off-midline tumors as postulated in previous studies with smaller wingless pathway medulloblastoma cohorts. Dense intratumoral blood-degradation products and cysts with blood contents are frequently found and might help to differentiate wingless pathway medulloblastoma from other medulloblastoma subtypes.
000147393 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000147393 588__ $$aDataset connected to CrossRef, PubMed,
000147393 7001_ $$00000-0003-3302-2719$$aMynarek, M.$$b1
000147393 7001_ $$00000-0002-9252-8923$$aPietsch, T.$$b2
000147393 7001_ $$00000-0002-5447-5322$$aPfister, S. M.$$b3
000147393 7001_ $$00000-0002-8573-8009$$aClifford, S. C.$$b4
000147393 7001_ $$00000-0002-3487-6508$$aGoschzik, T.$$b5
000147393 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, D.$$b6$$udkfz
000147393 7001_ $$00000-0002-1190-9469$$aSchwalbe, E. C.$$b7
000147393 7001_ $$00000-0002-7551-7464$$aHicks, D.$$b8
000147393 7001_ $$00000-0002-5446-9571$$aRutkowski, S.$$b9
000147393 7001_ $$00000-0001-5849-8671$$aBison, B.$$b10
000147393 7001_ $$00000-0003-1295-2685$$aPham, M.$$b11
000147393 7001_ $$00000-0002-3544-319X$$aWarmuth-Metz, M.$$b12
000147393 773__ $$0PERI:(DE-600)2025541-X$$a10.3174/ajnr.A6286$$gp. ajnr;ajnr.A6286v1$$n11$$p1811-1817$$tAmerican journal of neuroradiology$$v40$$x1936-959X$$y2019
000147393 909CO $$ooai:inrepo02.dkfz.de:147393$$pVDB
000147393 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-5447-5322$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000147393 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aExternal Institute$$b6$$kExtern
000147393 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000147393 9141_ $$y2019
000147393 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000147393 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000147393 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J NEURORADIOL : 2017
000147393 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000147393 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000147393 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000147393 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000147393 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000147393 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000147393 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000147393 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000147393 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000147393 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000147393 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000147393 980__ $$ajournal
000147393 980__ $$aVDB
000147393 980__ $$aI:(DE-He78)B062-20160331
000147393 980__ $$aI:(DE-He78)L101-20160331
000147393 980__ $$aUNRESTRICTED